ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 141 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2022. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $11,335,987 | +205.1% | 3,791,300 | 0.0% | 14.17% | +194.2% |
| Q3 2023 | $3,715,474 | -39.3% | 3,791,300 | -13.9% | 4.82% | -9.4% |
| Q2 2023 | $6,120,132 | -12.6% | 4,402,973 | 0.0% | 5.31% | -4.7% |
| Q1 2023 | $7,000,727 | -74.9% | 4,402,973 | -1.5% | 5.58% | -70.4% |
| Q4 2022 | $27,840,842 | -7.0% | 4,468,835 | 0.0% | 18.82% | -5.5% |
| Q3 2022 | $29,941,000 | +5.3% | 4,468,835 | 0.0% | 19.92% | +41.7% |
| Q2 2022 | $28,421,000 | +37.1% | 4,468,835 | 0.0% | 14.05% | +62.5% |
| Q1 2022 | $20,735,000 | -7.2% | 4,468,835 | 0.0% | 8.65% | -14.3% |
| Q4 2021 | $22,344,000 | -34.2% | 4,468,835 | +58.5% | 10.09% | -13.5% |
| Q3 2021 | $33,967,000 | -43.0% | 2,818,835 | 0.0% | 11.67% | -44.7% |
| Q2 2021 | $59,618,000 | -20.7% | 2,818,835 | +5.2% | 21.09% | -0.1% |
| Q1 2021 | $75,169,000 | +7.9% | 2,679,835 | 0.0% | 21.12% | +8.9% |
| Q4 2020 | $69,675,000 | -30.1% | 2,679,835 | 0.0% | 19.39% | -13.1% |
| Q3 2020 | $99,609,000 | -27.6% | 2,679,835 | 0.0% | 22.32% | -22.6% |
| Q2 2020 | $137,502,000 | +101.8% | 2,679,835 | 0.0% | 28.84% | +22.9% |
| Q1 2020 | $68,144,000 | -43.5% | 2,679,835 | 0.0% | 23.47% | -31.8% |
| Q4 2019 | $120,615,000 | +22.8% | 2,679,835 | 0.0% | 34.40% | +43.8% |
| Q3 2019 | $98,242,000 | -21.2% | 2,679,835 | 0.0% | 23.93% | -4.6% |
| Q2 2019 | $124,665,000 | +15.9% | 2,679,835 | 0.0% | 25.08% | +24.3% |
| Q1 2019 | $107,595,000 | -12.7% | 2,679,835 | 0.0% | 20.17% | -20.5% |
| Q4 2018 | $123,272,000 | +5.6% | 2,679,835 | +1.9% | 25.39% | +1.2% |
| Q3 2018 | $116,685,000 | +13.2% | 2,629,835 | 0.0% | 25.08% | +24.6% |
| Q2 2018 | $103,063,000 | -45.0% | 2,629,835 | +1.6% | 20.13% | -31.7% |
| Q1 2018 | $187,279,000 | +22.5% | 2,589,235 | +11.5% | 29.46% | +49.6% |
| Q4 2017 | $152,935,000 | +33.0% | 2,322,835 | +1.2% | 19.68% | +12.7% |
| Q3 2017 | $115,022,000 | +339.1% | 2,294,935 | +305.5% | 17.46% | +343.1% |
| Q2 2017 | $26,194,000 | – | 566,000 | – | 3.94% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital LLC | 1,637,125 | $27,684,000 | 5.54% |
| BVF INC/IL | 606,801 | $10,261,000 | 2.54% |
| Sarissa Capital Management LP | 633,000 | $10,704,000 | 2.36% |
| Glacier Peak Capital LLC | 38,048 | $989,000 | 0.85% |
| BB BIOTECH AG | 1,008,542 | $17,054,000 | 0.68% |
| FT Options LLC | 31,296 | $529,000 | 0.55% |
| Rhenman & Partners Asset Management AB | 150,000 | $2,537,000 | 0.50% |
| Virtus ETF Advisers LLC | 11,011 | $186,000 | 0.26% |
| DISCOVERY CAPITAL MANAGEMENT, LLC / CT | 806,105 | $13,631,000 | 0.20% |
| WASATCH ADVISORS LP | 759,183 | $12,519,000 | 0.19% |